Trial Profile

A Phase 2, Open-Label, Dose Escalation Trial Assessing the Safety, Tolerability, and Treatment Effect of Bel-sar (AU-011) With Suprachoroidal Administration in Subjects With Choroidal Metastasis From Breast or Lung Primary Tumors

Status: Not yet recruiting

Phase of Trial: Phase II

Latest Information Update: 26 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

24 Mar 2025 According to an Aura Biosciences media release, the company has sites activated with patients in prescreening. The Company expects initial data from this trial in 2025.
12 Nov 2024 According to an Aura Biosciences media release, the Company aims to enroll the first patients in a Phase 2 trial in 2024.
09 Aug 2023 According to an Aura Biosciences media release, company is on track to initiate the Phase 2 trial in 2024 with initial data by year-end 2024.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com